Item 5.07 Submission of Matters to a Vote of Security Holders

At the Portola Pharmaceuticals, Inc. (the "Company") 2020 annual meeting of stockholders held on June 12, 2020, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the 2020 annual meeting, filed with the Securities and Exchange Commission on April 20, 2020 (the "Proxy Statement"). The results of the matters voted upon at the meeting were:



      a)    Each of the Class I nominees of the Company's Board of Directors were elected to
            hold office until the Company's 2023 annual meeting of stockholders. The Class I
            nominees were: Jeffrey Bird, M.D., Ph.D.; 48,984,221 shares of Common Stock voted
            for, 1,241,675 withheld, and 13,340,539 broker non-votes; John H. Johnson;
            48,172,053 shares of Common Stock voted for, 2,053,843 withheld, and 13,340,539
            broker non-votes; and H. Ward Wolff; 48,697,269 shares of Common Stock voted for,
            1,528,627 withheld, and 13,340,539 broker non-votes. The terms of office of Class II
            directors Dennis M. Fenton, Ph.D., David C. Stump, M.D. and Ted W. Love, M.D.
            continue until the Company's 2021 annual meeting of stockholders. The terms of
            office of Class III directors Laura A. Brege, Scott Garland and Hollings C. Renton
            continue until the Company's 2022 annual meeting of stockholders.



      b)    The stockholders approved, on a non-binding, advisory basis, of the compensation
            of the Company's named executive officers as disclosed in the Proxy Statement:
            48,225,933 shares of Common Stock voted for, 1,900,229 against, 99,734 abstaining,
            and 13,340,539 broker non-votes.



      c)    The stockholders ratified the selection by the Audit Committee of the Company's
            Board of Directors of Ernst & Young LLP as the independent registered public
            accounting firm of the Company for its fiscal year ending December 31, 2020:
            62,613,691 shares of Common Stock voted for, 772,257 against, 180,487 abstaining,
            and 0 broker non-votes.


133289033 v2
--------------------------------------------------------------------------------

© Edgar Online, source Glimpses